Asthma is a respiratory disorder characterized by reversible airflow limitation, bronchial hyper-responsiveness and airway inflammation 1, 2 . Although it is clear that asthma is a heterogeneous syndrome, a prominent subset of asthma is characterized by type 2 inflammation with infiltration of type 2 helper T cells (T H 2 cells) into the airways and lung parenchyma, as well as by a molecular signature of airway epithelial cell exposure to T H 2 cytokines, especially interleukin 13 (IL-13) 3, 4 . IL-13 coordinates allergic lung inflammation through receptors on both structural cells and inflammatory cells. It induces epithelial cell hyperplasia and mucus production, airway smooth muscle cell hyper-responsiveness, and the recruitment of eosinophils 5 . IL-13 is a key driver of airway inflammation in mouse models of asthma 6 , and studies of the biomarkers of type 2 inflammation predict enhanced clinical benefit from treatment with antibodies that block IL-13 signaling, such as lebrikizumab 7 and dupilumab 8 .
The external signals and transcription factors that regulate T H 2 cell differentiation are well understood. The cytokine IL-4 is both the canonical product of T H 2 cells and a powerful driver of T H 2 cell differentiation. Naive CD4 + T cells require concurrent signaling via the T cell antigen receptor (TCR) and cytokines to induce T H 2 differentiation. TCR ligation activates T cells through a broad signaling cascade that includes the kinase PI(3)K and transcription factor NF-κB pathways. Signaling via the receptor for IL-4 activates the transcription factor STAT6, which upregulates expression of the transcription factor GATA-3 in activated T cells. Together these two key transcription factors promote T H 2 differentiation and cytokine production 9 . Because T H 2 differentiation is governed by a positive feedback loop of cytokines and transcription factors, it is very sensitive to minor changes in cytokine production, the strength of TCR stimulation, and other intrinsic and environmental factors. Extensive knowledge of the signals that control T cell differentiation and of methods to reproducibly manipulate this process in vitro make it a useful system for the study of basic principles that govern geneexpression networks and cell identity.
miRNAs regulate gene-expression programs by reducing the translation and stability of target mRNAs 10 . miRNAs are grouped into families that each share a network of predicted mRNA targets. Although the quantitative effect produced by each miRNA-target interaction is small, the combined effect of the network of miRNA-target interactions produces substantial changes in cell activity. Several studies have attempted to elucidate miRNA functions in asthma by analyzing miRNA expression in whole lung, airway epithelial cells or mixed peripheral blood lymphocytes from humans with asthma or mouse models of allergic airway inflammation [11] [12] [13] [14] . Such studies have provided insight into the effect of airway inflammation on miRNA expression patterns, but they have not defined cell-intrinsic effects of miRNA regulation on disease pathogenesis.
In T cells, miRNAs regulate proliferation, survival, activation, differentiation and cytokine production 15 . The miR-17~92 cluster has emerged as a particularly potent and pleiotropic regulator of T cell responses. This cluster is transcribed as a single primary miRNA (pri-miRNA) transcript that is processed to produce six mature miRNAs belonging to four miRNA families: the miR-17, miR-18, miR-19 and miR-92 families 16 . Primary miR-17~92 and the corresponding mature miRNAs are upregulated in activated CD4 + T cells and can promote the proliferation and survival of T cells [17] [18] [19] [20] .
Although they are expressed without apparent cell-type specificity, miRNAs in the miR-17~92 cluster regulate the differentiation and function of several distinct T cell subsets. Both miR-17 and miR-19b promote differentiation into the T H 1 and T H 17 subsets of helper T cells 18, 21 . These two miRNAs also inhibit inducible differentiation of regulatory T cells (T reg cells) in vitro 18 , but the cluster as a whole is required for normal T reg cell function in vivo 22 . Responses of follicular helper T cells (T FH cells) are reduced and dysregulated in the absence of miR-17~92 (refs. 23,24) . However, the regulation of T H 2 cell differentiation and cytokine production by miRNA remains poorly understood.
We hypothesized that miRNAs that are expressed differently in airway-infiltrating T cells in asthma regulate T H 2 cell function and promote lung inflammation. We used a highly sensitive nanoscale microfluidic quantitative PCR (qPCR) approach to profile miRNA expression in CD4 + T cells isolated from human asthmatic airways 25, 26 . miR-19a, a member of the miR-17~92 cluster, was substantially upregulated in asthma. Through the use of genetically engineered mice, we found that miR-17~92 promoted T H 2 cytokine production in vitro and type 2 inflammation in vivo. We mapped the regulation of T H 2 cytokine production by miR-17~92 to the miR-19 family through the use of transfectable miRNA mimics and inhibitors in primary human and mouse T cells. A functional screen of the network of miR-19 targets in T H 2 cells revealed several signaling inhibitors that restrained IL-13 and IL-4 production. Together our data indicate that the observed increase in T cell miR-19a expression in humans with asthma may augment T H 2 responses in their airways.
RESULTS miRNA expression in airway CD4 T cells
To investigate miRNA expression in airway-infiltrating T cells, we profiled the expression of a panel of 190 miRNAs in CD4 + T cells sorted from bronchoalveolar lavage (BAL) fluid from 8 healthy, 13 steroid-naive asthmatic and 21 steroid-using asthmatic human subjects 12 (Table 1) . We extracted RNA from sorted CD3 + CD4 + T cells, and assessed miRNA expression by nanoscale microfluidic qPCR on 100 pg RNA from each subject ( Supplementary Fig. 1a and Supplementary Table 1 ). Our analysis revealed few differences between asthmatic and healthy CD4 + T cells from BAL fluid in their miRNA expression, with one notable exception ( Supplementary Fig. 1b and Supplementary Table 2) . Of the 89 miRNAs that we detected in at least 60% of the subjects, miRNA-19a had the most significantly elevated expression in asthma (Fig. 1a and Supplementary Table 2 ; P = 0.0199). miR-19a expression was consistently elevated in all of the steroid-naive asthmatic subjects, with very little variability, and was similarly elevated in the steroid-using asthmatic subjects, who were treated with the inhaled corticosteroid (ICS) budesonide (Fig. 1b) . This miRNA remained elevated in CD4 + T cells from steroid-naive asthmatics after 6 weeks of ICS treatment (Fig. 1c) , which indicated that it was resistant to gene-expression changes induced by steroid treatment. Because miR-19a is a member of the miR-17~92 cluster, a highly conserved cluster of six miRNAs transcribed in one polycistronic pri-miRNA, we investigated the expression of other members of the cluster. Only miR-19a, and not miR-19b, miR-17, miR-18a or miR-20a, was expressed differently in CD4 + T cells from asthmatic subjects than in CD4 + T cells from healthy subjects (Fig. 1d) . These data demonstrated that expression of miR-19a was specifically elevated in airway T cells in asthma and indicated that individual members of the miR-17~92 cluster were regulated differently in this setting.
miR-17~92 promotes T H 2 cytokine production
The miR-17~92 cluster regulates, with varying degrees of potency, the differentiation and effector functions of several helper T cell subsets, including T H 1 cells, T H 17 cells, T FH cells and T reg cells [19] [20] [21] [22] [23] [24] . However, the cluster's role in T H 2 cell differentiation and cytokine production, important features of the asthmatic immune response, has not been explored. To investigate this, we cultured miR-17~92-deficient CD4 + T cells (called '17~92 ∆ ' cells here), miR-17~92-sufficient control CD4 + T cells (called '17~92 +' cells here) and transgenic CD4 + T cells overexpressing miR-17~92 (called '17~92 tg ' cells here) in T H 2-polarizing conditions. Intracellular cytokine staining revealed that 17~92 tg cells produced more of the type 2 cytokine IL-13 than did their 17~92 + counterparts (Fig. 2a) . Conversely, fewer 17~92 ∆ cells than 17~92 + control cells produced the type 2 cytokines IL-13, IL-5 and IL-4 ( Fig. 2a,b ). This defect in T H 2 differentiation and cytokine production did not result in increased production of T H 1 cytokines, as measured by production of interferon-γ (IFN-γ) (Fig. 2c) . 17~92 ∆ cells produced substantially more tumor-necrosis factor, a known direct target of miR-19 ( Fig. 2c) , which suggested that these cells were capable of efficient cytokine production in T H 2-polarizing conditions and that the defect was limited to type 2 cytokines. 17~92 ∆ cells produced fewer T H 2 cytokines, even among established GATA-3 hi T H 2 cells (Fig. 2d) . Thus, the miR-17~92 cluster positively regulated T H 2 cytokine production.
To determine whether the T H 2 cytokine defect was cell intrinsic, we cultured congenically marked 17~92 ∆ CD4 + T cells together with 17~92 + CD4 + T cells in T H 2 conditions. After 5 d in culture, the CD45.1 + 17~92 ∆ T cells produced less IL-13 and IL-4 than did CD45.2 + 17~92 + cells (Fig. 3a) , which demonstrated that the cytokine defect was cell intrinsic and did not entirely depend on feedback from IL-4 or other products produced by the mutant T cells in culture.
In T H 2 cell cultures, we observed a slight proliferation defect in 17~92 ∆ and slightly greater proliferation of 17~92 tg cells, compared with the proliferation of 17~92 + cells (Fig. 3b) . To determine whether the frequency of T H 2 cytokine-producing cells among 17~92 ∆ , 17~92 + or 17~92 tg CD4 + T cells was an indirect result of their rate of proliferation, we labeled the cells with the division-tracking dye CellTrace Violet and analyzed cytokine production at each division after 5 d of culture in T H 2-polarizing conditions. The production of IL-13 and cluster; miR-92a was not detected in this experiment), normalized to the global mean: each symbol represents an individual subject; horizontal lines indicate the mean. NS, not significant; *P < 0.05, **P < 0.0001 (one-way analysis of variance (ANOVA) with Dunnett's post-test (compared with healthy controls; b,d) or paired two-tailed t-test (c)). Data were pooled from two experiments with 8 healthy subjects, 13 steroid-naive asthmatic subjects and 21 steroid-using asthmatic subjects (c includes subset of the steroid-naive asthmatic subjects in a,b,d for which data before and after ICS were available).
IL-5 in 17~92 + cells did increase with each division (Fig. 3c,d ).
However, 17~92 ∆ cells produced significantly less IL-13, IL-5 and IL-4 at each cell division than did 17~92 + cells (Fig. 3c,d ). In contrast, 17~92 tg cells produced more IL-13 and IL-5 at each division, but produced an amount of IL-4 equal to that produced by 17~92 + cells ( Fig. 3c,d ). Together these data indicated that the miR-17~92 cluster promoted type 2 cytokine production in a cell-intrinsic and proliferation-independent manner.
miR-19 augments T H 2 differentiation
To understand the mechanism by which miR-17~92 controls cytokine production in T H 2 cells, we needed to examine the functions of individual miRNA members of the cluster. Therefore, we transfected mature miRNA mimics corresponding to each of the six miRNAs in the miR-17~92 cluster into 17~92 ∆ CD4 + T cells on days 1 and 4 of T H 2-polarizing cultures. Transfection of either miR-19a or miR-19b was sufficient to completely restore T H 2 cytokine production ( Fig. 4a-c) . Other miRNAs within the cluster conferred only partial restoration of T H 2 cytokine production compared with the restoration achieved by miR-19a or miR-19b. These data indicated that miR-19 was the primary component of the miR-17~92 cluster that augmented T H 2 differentiation. All of the miR-19a and a large majority of the miR-19b expressed in T cells derived from the miR-17~92 cluster (Supplementary Fig. 2 ). Consistent with that finding, specific retroviral sensors of the activity of miR-19a and miR-19b were strongly repressed in 17~92 + cells but not in 17~92 ∆ cells (Supplementary Fig. 3 ). T cell activation induces increased transcription of the miR-17~92 cluster, and all of the miRNAs in the cluster continued to have high expression during T H 2 cell differentiation 27 (data not shown). A single transfection either early (day 1) or late (day 4) in the culture did not restore T H 2 cytokine production (Fig. 4d,e) . We concluded that miR-19 was required throughout T H 2 polarization to support robust T H 2 differentiation and cytokine production. miR-19 mimics also modestly increased proliferation of 17~92 ∆ cells in T H 2 conditions (Supplementary Fig. 4) .
We next investigated whether modulating the activity of miR-19 alone was sufficient to alter type 2 cytokine production in miR-17~92-sufficient T cells with normal endogenous expression of the other miRNAs in the cluster. Transfection of inhibitors of miR-19a and miR-19b into 17~92 + T cells specifically increased the expression of corresponding sensors 20 (Online Methods) of the activity of miR-19a and miR-19b and decreased expression of IL-13 ( Supplementary Fig. 3 ). These inhibitors also significantly reduced production of IL-13, but not IL-4, when transfected into CD4 + T cells obtained from human cord blood and cultured in T H 2-polarizing cultures (Fig. 5a,b) . Conversely, transfection with the miR-19a mimic was sufficient to increase the expression of IL-13, but not that of IL-4, in CD4 + T cells from human cord blood (Fig. 5c,d) . Similarly, 17~92 + mouse CD4 + T cells had increased production of IL-13, but not of IL-4, when transfected with mimics of miR-19a or miR-19b in nonpolarizing conditions ( Supplementary  Fig. 3) . We concluded that changes in miR-19 expression, such as those seen in human asthmatic airway T cells, were sufficient to modulate the abundance of IL-13 produced in primary human and mouse CD4 + T cells.
miR-19 targets Pten, Socs1 and Tnfaip3
Because a large number of direct miR-19 targets have been validated in B cell lymphomas and other cell types, we took a candidate approach to investigate how miR-19 augments T H 2 differentiation. We individually inhibited the 38 previously confirmed miR-19 targets [28] [29] [30] that are expressed in T cells 31 through the use of small interfering RNA (siRNA) in 17~92 ∆ CD4 + T cells during T H 2 polarization (Supplementary Table 3) . We calculated z-scores for IL-13 and IL-4 for each of the transfections (Fig. 6a,b) . We further tested the top eight candidate genes whose inhibition increased IL-13 and IL-4 by inhibition with three individual siRNAs per gene in 17~92 ∆ CD4 + T cells during T H 2 polarization to confirm the 'rescue' of IL-13 and IL-4 (Fig. 6c,d) . The type 2 cytokine defect of 17~92 ∆ cells was 'rescued' by inhibition of Pten, Socs1 and Tnfaip3 (which encodes A20) with at least two of three individual siRNAs (Fig. 6e) . To confirm that miR-19 inhibited each of the top eight candidate genes, we analyzed gene expression by qPCR in 17~92 ∆ cells transfected with miR-19a, miR-19b or control mimics, compared with that in 17~92 + cells (Fig. 6f) . Furthermore, to determine whether genetic depletion of PTEN expression in 17~92 ∆ cells was able to restore T H 2 cytokine production, we deleted one allele of Pten in 17~92 ∆ cells (17~92 ∆ Pten +/− ). Genetic depletion of PTEN moderately 'rescued' the cytokine defect of 17~92 ∆ T cells (Fig. 6g) .
Pten, Socs1 and Tnfaip3 encode negative regulators of T cell signaling pathways that are important for all helper T cell subsets. To determine whether each of these targets regulated other helper T cell cytokines, such as IFN-γ, IL-17A and IL-17F, we transfected 17~92 ∆ cells with individual siRNAs targeting Pten, Socs1 and Tnfaip3 (Fig. 6h-j) . Consistent with published reports 18, 21 , inhibition of Pten increased the production of all T helper cytokines tested, whereas reducing the expression of Socs1 or Tnfaip3 enhanced the production of T H 2 cytokines but not that of IFN-γ or IL-17. Thus, miR-19 specifically regulated T H 2 responses through distinct limiting mRNA targets.
miR-17~92 augments T H 2 cell function in vivo We next investigated whether the diminished production of T H 2 cytokines by 17~92 ∆ T cells would result in altered type 2 inflammation in airways in vivo. We transferred 17~92 ∆ or 17~92 + ovalbumin (OVA)-specific OT-II T H 2 cells (cells with transgenic expression of a major histocompatibility complex class II-restricted TCR) into
Cd28 −/− mice and challenged the recipient mice every 24 h oropharyngeally with OVA for 3 d (Supplementary Fig. 5a ). At 18 h after the final challenge, we analyzed pulmonary resistance in response to increasing doses of acetylcholine. Mice that received either no OT-II cells or 17~92 ∆ OT-II T H 2 cells had significantly lower pulmonary resistance than that of mice that received 17~92 + OT-II T H 2 cells (Fig. 7a ), which indicated that T H 2 cells that lacked the miR-17~92 cluster were less capable of inducing allergic airway hyper-responsiveness. Histological analysis of lung sections from these mice revealed a greater abundance of mucus-secreting goblet cells and more severe inflammation in mice that received 17~92 + OT-II T H 2 cells than in those that received 17~92 ∆ OT-II T H 2 cells (Fig. 7b-d) . Mice that received 17~92 ∆ OT-II T H 2 cells transfected with the miR-19a mimic showed a trend toward increased inflammation and mucus secretion ( Fig. 7b-d ). To better characterize and quantify airway inflammation, we analyzed BAL fluid from the recipient mice by flow cytometry ( Supplementary  Fig. 5b ). Mice that received 17~92 ∆ OT-II T H 2 cells had significantly less eosinophilia in the airways than did mice that received 17~92 + OT-II T H 2 cells (Fig. 7e) . However, transfection of 17~92 ∆ OT-II T H 2 cells with miR-19a induced airway eosinophil infiltration similar to that seen in recipients of 17~92 + OT-II T H 2 cells (Fig. 7e) . Macrophage and neutrophil numbers were relatively similar in all three groups of recipients (Fig. 7e) , which suggested that the differences in airway inflammation were restricted to effects induced by type 2 cytokines. We concluded that the miR-17~92 cluster, and miR-19a specifically, had a role in the in vivo function of T H 2 cells as inducers of the allergic inflammatory phenotype associated with asthma. npg DISCUSSION Guided by miRNA expression in T cells present in the airways in human asthma, we identified a miRNA that augmented T H 2 cytokine production and allergic inflammation via coordinated regulation of cytokine and antigen receptor signaling pathways. Our data demonstrated that the miR-17~92 cluster, and specifically miR-19a, promoted T H 2 cytokine production by simultaneously targeting inhibitors of the NF-κB, STAT and PI(3)K pathways. In the context of published studies of the miR-17~92 cluster, our findings have illustrated basic principles of miRNA regulation, including the network 'logic' of miRNA function and the way that complex biological processes such as effective T cell-mediated immune responses emerge from coordinated miRNA regulation of diverse aspects of cell activity. The miR-17~92 cluster has many established functions in lymphocytes 32 . The cluster as a whole promotes the proliferation and survival of T cells as well as the differentiation and function of several committed effector T cell subsets 18, 19, [21] [22] [23] [24] , which makes it an important coordinator of T cell responses. T FH cell responses involve the concerted action of all four miRNA families in the miR-17~92 cluster 23, 24 . miRNAs of the miR-17 and miR-92 families support T cell proliferation in the absence of other miRNAs 20 . In our experiments, miRNAs of the miR-19 family, as well as those of the miR-17 family and miR-92 family, partially restored the proliferation of 17~92 ∆ T cells. Both miR-17 and miR-19b promote survival of T cells and differentiation of T H 1 and T H 17 cells while limiting differentiation of induced T reg cells 18, 21 . However, no specific functions have previously been attributed to miR-19a in helper T cells. We mapped the T H 2-cytokine-promoting activity of the miR-17~92 cluster to miR-19, as both miR-19a and miR-19b restored the production of IL-13 and IL-4 in 17~92 ∆ T cells, but other miRNAs in the cluster did not.
Our study has emphasized an important concept about the mechanism by which miRNAs regulate cell activity: a single miRNA can be expressed in and regulate many different cell types through distinct but overlapping networks of targets. Each target may have a limiting A r t i c l e s role in distinct differentiation environments or may have a similar role in a variety of contexts. For example, miR-19 regulated the production of T H 2 cytokines in part through PTEN, a target that has widespread effects on effector programs of helper T cells 18, 19, 21, 23 .
In contrast, SOCS1 and A20 were limiting factors for the production of T H 2 cytokines but not for that of T H 1 or T H 17 cytokines. The same concept applies to transcription factors and their target genes. For example, c-Maf regulates production of both T H 2 cytokines and T H 17 cytokines through distinct molecular pathways. Similarly, GATA-3 is the principal determinant of T H 2 cell differentiation and a direct regulator of Il13 and Il5, but it also regulates T cell development in the thymus and survival in the periphery. Our findings have demonstrated that careful delineation of target networks might reveal not only the mechanisms through which transcription factors and miRNAs mediate their functions but also novel or unexpected limiting requirements for downstream genes and pathways that coordinate T cell-mediated immunity. We identified at least three important pieces of the miR-19 target network in T H 2 cells: Pten, Socs1 and Tnfaip3. Each of these target mRNAs encodes an inhibitor of a distinct signaling pathway, which indicated that miR-19 augmented the production of T H 2 cytokines by simultaneously amplifying signaling via PI(3)K, Jak-STAT and NF-κB. However, our analysis revealed a limiting independent role for each target, as depleting each individually was sufficient to markedly increase T H 2 cytokine production. These pathways are all essential components of the signaling via receptors for antigens and cytokines that induces the differentiation and effector function of T cells.
PTEN inhibits the PI(3)K pathway, which promotes T cell proliferation and cell survival 33 , and deletion of one allele of Pten results in autoimmunity and lymphoproliferative disease in mice 34 . PTEN is an important target of miR-17~92 in the differentiation of T H 1 cells, T H 17 cells and T FH cells 18, 21, 23, 24 , but its effects on cytokine production by T H 2 cells have remained unknown. Genetic 'rescue' of PTEN overexpression in 17~92 ∆ cells partially restored the production of T H 2 cytokines, which indicated that both PTEN and other targets contributed substantially to the T H 2 phenotype.
SOCS1 inhibits the Jak-STAT pathway downstream of cytokine receptors 35 and favors T H 17 differentiation over T H 1 differentiation by repressing signaling downstream of IL-12 and IFN-γ 36,37 .
Production of both IFN-γ and IL-4 is greater in CD4 + T cells in SOCS1-deficient mice than in wild-type mice 38 , and SOCS1 inhibits IL-4 signaling in macrophages 39 . Such findings have led to speculation that SOCS1 may inhibit T H 2 responses 40 , but this possibility had remained untested before our experiments, to our knowledge. Furthermore, SOCS1 has not been reported to be an important target of miR-17~92 in regulating the differentiation and effector functions of any helper T cell subset.
Tnfaip3 encodes A20, a constitutively expressed negative regulator of the NF-κB pathway in T cells. A20 has been identified as an important target of miR-19 in macrophages 30 . Inhibition of A20 increases IL-2 production in Jurkat cells 41 , but its effect on T H 2 cytokine production had not yet been described, to our knowledge. Identification of these three targets will improve understanding of the intracellular components that regulate T H 2 cytokine production. Genome-wide approaches to determine the full miR-19 target network in T H 2 cells would probably reveal additional targets involved in helper T cell biology.
We hypothesized that miRNA-expression profiling in airwayinfiltrating T cells might reveal functionally relevant miRNAs and pathways that are directly involved in asthma pathogenesis. Indeed, we identified miR-19a as a candidate regulator of T H 2 responses through miRNA profiling 25, 26 in the small number of CD4 + T cells that could be recovered from BAL fluid. Published studies have identified miRNAs of interest by profiling expression in complex cell mixtures, such as whole lungs in animal models 14 , epithelial cell brushings 12 or mixed lymphocytes from peripheral blood of asthmatic subjects 11, 42 . Interpretation of data from unseparated tissues can be ambiguous. Differences in miRNA expression might reflect changes in the cellular composition of samples from asthmatic subjects, and the formation of mechanistic hypotheses about disease pathogenesis will require further work to identify which cell type(s) exhibit differences in the expression of any miRNA of interest. Additional studies are needed to confirm the observed increase in miR-19a in airway CD4 + T cells in asthma and to determine whether this change is limited to T H 2 cells in this context. Larger studies may also identify correlations between miR-19a expression and asthma severity, lung function, response to corticosteroid treatment, or biomarkers of T H 2 inflammation that stratify asthma phenotypes 1, 43 . Although clusters of miRNAs are transcribed as a single polycistronic pri-miRNA transcript, each mature miRNA in the cluster is not necessarily expressed at the same abundance in a given cell type and condition. Nevertheless, we were surprised to find an increase specifically in miR-19a, not other members of the miR-17~92 cluster, in airway-infiltrating T cells in asthma. miR-19a and miR-19b are also 'preferentially' increased in premalignant cells in a mouse model of B cell lymphoma and in human Burkitt's lymphoma cell lines 16 . A specific increase in miR-19a might be mediated by 'preferential' processing from the polycistronic miR-17~92 pri-miRNA transcript or by a sequence-specific increase in the efficiency of some other step in miR-19a biogenesis. Alternatively, mature miR-19a might be specifically stabilized in T cells in inflamed lungs. Regardless of the mechanism, the observed increase in miR-19a abundance should have a substantial effect on the secretion of IL-13, as altering miR-19a activity by overexpression or depletion in both human and mouse primary T cells altered IL-13 production in vitro.
The identity and function of miRNAs that regulate type 2 inflammation in a T cell-intrinsic manner have remained uncertain. miR-155 has been a major focus because miR-155-deficient T cells have a modest bias toward T H 2 differentiation in vitro 44, 45 and miR-155-deficient mice develop partially penetrant spontaneous airway remodeling with some of the characteristics of asthma 44 . However, these mice are resistant to experimentally induced airway inflammation 46 , which suggests that miR-155 might have a role in cell types other than T H 2 cells in this model. Our data suggested that upregulation of miR-19a in T cells in asthmatic airways might be an indicator and a cause of increased IL-13 production and probably contributed to type 2 inflammation in asthma. Indeed, 17~92 ∆ T H 2 cells induced far less airway eosinophilia than did 17~92 + T H 2 cells in an allergic airway inflammation model, and restoration of miR-19a was sufficient to 'rescue' this defect.
Our study has linked miR-19a activity with human asthma and has identified mechanisms of miR-19a function in T cells, which suggests that miR-19 might be a useful drug target. Published animal model studies have confirmed the concept of miRNA-based therapy through the use of intranasal administration of sequence-specific miRNA inhibitors to ameliorate allergic airway inflammation 13, [47] [48] [49] . In addition, identifying the target networks through which miRNAs act may be an effective path to the development of novel therapies. For example, our findings lend weight to the argument that NF-κB inhibitors might be effective in asthma and other allergic diseases 50 . Through the coordinated repression of several mRNA targets, miR-19 amplified signals that augmented production of T H 2 cytokines, the principle drivers of asthma pathogenesis.
METHODS
Methods and any associated references are available in the online version of the paper. 
